Intravenous secretin for autism spectrum disorders (ASD).

Background: In 1998 secretin, a gastrointestinal hormone, was suggested as an effective treatment for autism spectrum disorders (ASD) based on anecdotal evidence.

Objectives: To assess whether intravenous secretin improves the core features of ASD, other aspects of behaviour or function such as self-injurious behaviour, and the quality of life of affected individuals and their carers. We also assessed whether secretin causes harm.

Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).

Background: Autism spectrum disorders (ASD) are characterised by abnormalities in social interaction and communication skills, as well as stereotypic behaviours and restricted activities and interests. Selective serotonin reuptake inhibitors (SSRIs) are prescribed for the treatment of co-morbidity associated with ASD such as depression, anxiety and obsessive-compulsive behaviours.

Objectives: To determine if treatment with an SSRI: 1.

Iron supplementation for breath-holding attacks in children.

Background: Breath-holding attacks are common during childhood. Iron supplementation has been claimed to reduce the frequency or severity, or both, of breath-holding attacks in children.

Objectives: To assess the effect of iron supplementation on the frequency and severity of breath-holding attacks in children.

Interventions for increasing ankle range of motion in patients with neuromuscular disease.

Background: Reduced ankle dorsiflexion range of motion, or ankle equinus, is a common and disabling problem for patients with neuromuscular disease. Clinicians devote considerable time and resources implementing interventions to correct this problem although few of these interventions have been subject to rigorous empirical investigation.

Objectives: To assess the effect of interventions to reduce or resolve ankle equinus in people with neuromuscular disease.